Image module

PL-001 is Proteolytics’ novel product candidate, that combines OPAL-A with the Company’s proprietary ProteoActiv™ technology to treat hard-to-heal wounds, including pressure ulcers, venous ulcers, diabetic foot ulcers and burns.

Proteolytics is progressing a development path to achieve FDA, EMA and TGA approval in order to launch PL-001 as a registered product.

Proteolytics will evaluate opportunities to out-license PL-001 following clinical proof-of-concept.